← Back to patent-cliff list
Riluzole (Aquestive Therapeutics)
Tier C — Watch / tradeRiluzole (Aquestive Therapeutics)
Aquestive Therapeutics Inc
Originator
2019
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SCNA
Brand：Exservan, Emylif
Indications (approved)：Amyotrophic lateral sclerosis
Regional status
US
Withdrawn
EU
Approved
2022-10-25
China
Discontinued
2023-05-10
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Riluzole (Aquestive Therapeutics)?
Approved indications include: Amyotrophic lateral sclerosis.
When does the Riluzole (Aquestive Therapeutics) patent expire?
No public expiry year is available for Riluzole (Aquestive Therapeutics) yet; this page updates once verified.
How do I get a quote for Riluzole (Aquestive Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29